Dabigatran and rivaroxaban concentration-dependently inhibited tissue factor-induced thrombin generation and platelet aggregation in vitro, with rivaroxaban showing stronger inhibition.
Does dabigatran or rivaroxaban inhibit tissue factor-induced thrombin generation and platelet aggregation in vitro in blood from healthy adults?
Both dabigatran and rivaroxaban concentration-dependently inhibit tissue factor-induced hypercoagulation and platelet activation in vitro, with rivaroxaban displaying stronger inhibition.
Dabigatran and rivaroxaban may simultaneously inhibit coagulation and platelet activation. This study aimed to reveal the in-vitro effects of dabigatran and rivaroxaban on thrombin generation and platelet aggregation (PAg) derived via tissue factor (TF) pathway. Citrated blood was obtained from six healthy adults (26-60 years old) and pretreated with increasing concentrations of dabigatran or rivaroxaban. Plasmatic endogenous thrombin potential (ETP) was measured by the calibrated automated thrombogram method. The whole blood PAg was evaluated via a kinetic counting method. TF produced an ETP of 1904.69 ± 121.42 nmol min and a PAg of 78 ± 5%. Dabigatran and rivaroxaban concentration-dependently reduced ETP with half-maximal inhibitory concentrations of 460.1 ± 1.4 and 678.1 ± 1.4 nmol/l, and inhibited PAg with half-maximal inhibitory concentrations of 119.5 ± 1.5 and 77.5 ± 1.6 nmol, respectively. Dabigatran and rivaroxaban significantly inhibit TF-induced hypercoagulation and platelet activation in vitro in a concentration-dependent manner. Rivaroxaban displays stronger inhibition on thrombin generation and PAg than dabigatran.
Wan et al. (Tue,) conducted a other in Healthy (n=6). Dabigatran and rivaroxaban was evaluated on Endogenous thrombin potential (ETP) and platelet aggregation (PAg). Dabigatran and rivaroxaban concentration-dependently inhibited tissue factor-induced thrombin generation and platelet aggregation in vitro, with rivaroxaban showing stronger inhibition.